Skip to main content
. Author manuscript; available in PMC: 2024 Nov 11.
Published in final edited form as: J Thromb Haemost. 2022 Dec 22;21(3):586–598. doi: 10.1016/j.jtha.2022.11.022

FIGURE 3.

FIGURE 3

Enhanced ADAMTS13 activity does not affect endotoxemia-associated thrombosis outcomes. (A) VWF:Ag and (B) ratios of VWF:CB to VWF:Ag in blood samples collected prior to (Pre) and 24h after (Post) the stenosis procedure from mice receiving vehicle control (n = 10) or recombinant human ADAMTS13 (rhADAMTS13) (n = 11). (C) Thrombus incidence and (D) thrombus weights (>0 mg) of vehicle control and rhADAMTS13-treated mice at 24h post-stenosis. Pooled plasma from normal C57Bl/6 mice was used as the reference for all assays. **p < .01, ****p < .0001. ns, not significant; VWF:Ag, plasma von Willebrand factor; VWF:CB, von Willebrand factor–collagen binding activity.